13F Holdings
中文EN

PGEN PRECIGEN, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1356090 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY109.9%
TTM EPS YoY107.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin21.4%
Net margin15.6%
FCF margin-47.4%
EBITDA margin23.9%

Returns

ROE38.8%
ROA12.7%
ROIC (approx.)23.5%
Asset turnover0.82x

Leverage & solvency

Liabilities / assets60.5%
Debt / equity1.12x
Current ratio5.58x
Interest coverage2.85x

Cash quality & payout

Operating cash flow / net income-3.00x
Accruals ratio50.9%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$9.68M$3.92M$6.22M$26.91M$14.27M
R&D expense$41.33M$53.07M$48.61M——
SG&A expense$70.13M$41.29M$40.41M——
Operating income-$110.51M-$135.03M-$99.76M——
Interest expense$3.87M$6,000$468,000——
Pretax income-$250.64M-$128.03M-$96.36M-$79.97M-$110.97M
Income tax$3,000-$1.79M-$458,000-$189,000-$160,000
Net income-$250.64M-$126.23M-$95.90M$28.32M-$92.17M
EBITDA-$107.31M-$130.50M-$93.09M——
EPS (basic)-1.37-0.47-0.390.14-0.47
EPS (diluted)-1.37-0.47-0.390.14-0.47
Weighted avg. shares (diluted)312.98M267.73M244.54M200.36M197.76M
Balance sheet
Cash & equivalents$30.23M$29.52M$7.85M$48.60M$43.34M
Short-term investments$67.62M$68.39M$55.28M$51.09M$72.24M
Receivables$3.92M$926,000$902,000$978,000$1.34M
Inventory$9.58M$0—$287,000$326,000
Current assets$115.23M$102.41M$68.75M$118.16M$156.63M
PP&E, net$13.76M$13.83M$7.11M$7.33M$8.60M
Goodwill$15.23M$19.14M$26.61M$36.92M$37.55M
Intangibles$3.18M$4.46M$40.70M$44.45M$52.29M
Total assets$155.50M$145.27M$151.04M$215.98M$359.86M
Current liabilities$37.31M$21.52M$22.98M$78.64M$34.65M
Short-term debt——$0$43.22M$52,000
Long-term debt$93.17M$0—$0$179.88M
Total debt$93.17M$0—$43.22M$179.93M
Total liabilities$134.59M$78.53M$32.55M$89.72M$252.51M
Shareholders' equity$20.91M$38.51M$118.50M$126.26M$107.35M
Net debt$62.94M-$29.52M—-$5.38M$136.59M
Shares outstanding353.91M292.87M248.92M208.15M206.74M
Cash flow statement
Operating cash flow-$87.83M-$68.17M-$66.93M-$65.05M-$55.77M
Capital expenditure$2.00M$8.58M$1.54M$4.92M$7.25M
Free cash flow-$89.83M-$76.76M-$68.47M-$69.97M-$63.02M
Investing cash flow-$1.53M-$20.71M-$3.09M$226.42M-$74.54M
Financing cash flow$90.05M$110.58M$29.59M-$155.29M$121.19M
Depreciation & amortization$3.20M$4.53M$6.67M$10.77M$13.76M
Stock-based compensation$10.87M$9.47M$9.89M$10.21M$13.90M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.